SEC Form 4 · accession 0000899243-18-022378
AILERON THERAPEUTICS INC · ALRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P Longenecker Ph.D.
Officer — President and CEO
Period of report
Aug 10, 2018
Accepted (ET)
Aug 14, 2018 · 7:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001420565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 10, 2018 | P | 10,000 | $2.45 | A | 10,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.40 to $2.48, inclusive. The reporting person undertakes to provide to Aileron Therapeutics, Inc., any security holder of Aileron Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.